Pharma Equity Group A/S (CPH:PEG)

Market Cap	105.57M -39.0%
Revenue (ttm)	n/a
Net Income	-21.02M
EPS	-0.02
Shares Out	1.23B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	321,029
Average Volume	265,324
Open	0.0822
Previous Close	0.0860
Day's Range	0.0802 - 0.0858
52-Week Range	0.0706 - 0.1500
Beta	0.92
RSI	42.97
Earnings Date	Mar 18, 2026

About Pharma Equity Group

Pharma Equity Group A/S, through its subsidiary, Reponex Pharmaceuticals A/S, a clinical-stage biopharmaceutical company, develops treatments for diseases that have patient and social impact for which current therapy is lacking or in need of improvement. Its products under development that are in Phase II clinical trials include RNX-011 for the treatment of bacterial peritonitis; RNX-021, RNX-022, and RNX-023 for the treatment of Ulcus Cruris chronic skin ulcers; RNX-041 for the treatment of inflammatory bowel diseases, such as chrons and pouch...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Denmark
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: PEG